PEPFAR

Meharry Medical College Launches Nation’s First School of Global Health

Retrieved on: 
Monday, November 13, 2023
Diabetes, Health, Other Health, Training, Other Education, Continuing, University, Practice Management, Managed Care, Education, General Health, Hospitals, Fitness & Nutrition, Nursing, JD, Social, Global health, Health equity, STEM, DHL, Meharry Medical College, Global Health, Congress, Trustee, MBA, Mental health, Medical college, The Kresge Foundation, Knowledge, School, CVS Health, HIV, Behavioural sciences, American Public Health Association, Doctor of Public Health, Public health, PEPFAR, CVS Caremark, Female, Public, Medicine, Student, MCP, Accreditation, HBCU, Together for Change, BSPH, Research, Policy, Hope, LLP, FACC, Morehouse School of Medicine, Faculty, COVID-19, MPH, Human, Management, Pharmaceutical industry, Doctor of Philosophy

Meharry Medical College is advancing its work to eliminate global health inequities by establishing the first School of Global Health in the United States.

Key Points: 
  • Meharry Medical College is advancing its work to eliminate global health inequities by establishing the first School of Global Health in the United States.
  • The School is an outgrowth of the Institute of Global Health Equity, which Meharry launched in February of 2023.
  • The Meharry Board of Trustees unanimously approved Meharry establishing the School of Global Health at a meeting in October.
  • "As a former president of Meharry Medical College, it brings me great joy to witness the launch of the School of Global Health, which will be a global health equity pioneer," said Dr. David Satcher, the 16th U.S.

Over $3.7 million in NIH grants will fund research on impacts of climate change on HIV-related health outcomes

Retrieved on: 
Wednesday, October 18, 2023
WHO, CUNY, Research, UCSB, Graduate Center, CUNY, National Institute of Allergy and Infectious Diseases, Weather, UCSF, Temperature, Population health, Health, Health equity, Science, Public health, Global Climate and Health Alliance, Implementation Science, Climate, NIAID, Icahn School of Medicine at Mount Sinai, HIV, Diabetes, Food, R01, University, Geographic Locator Codes, PEPFAR, Medicine, Risk, HIV/AIDS, Hypertension, Mount Sinai, Health policy, NIH, SIG, Climate change, Area studies, UNAIDS, Drug resistance, Infection, Epidemiology, Pharmaceutical industry, Agriculture, Central Africa

"These climate-related factors likely also increase the risk of poor clinical outcomes among people living with HIV."

Key Points: 
  • "These climate-related factors likely also increase the risk of poor clinical outcomes among people living with HIV."
  • Work on the four-year R01 award will combine data sources uniquely suited to characterize the influence of extreme weather on HIV care outcomes.
  • This, in turn, can inform strategies to help mitigate the impacts of climate change and extreme weather on HIV care outcomes and the trajectory of the HIV pandemic.
  • The team is currently recruiting for a full-time Postdoctoral Fellow to focus on climate and health research, as well as a full-time Project Manager , to join the project team.

Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV

Retrieved on: 
Tuesday, September 5, 2023
HIV/AIDS, CHAI, Joint United Nations Programme on HIV/AIDS, HIV, MPP, Food and Drug Administration, ARV, Subtypes of HIV, ViiV Healthcare, Medicines Patent Pool, Tablet, Patient, PEPFAR, President's Emergency Plan for AIDS Relief, WHO, Abacavir/dolutegravir/lamivudine, FDA, Safety, UNAIDS, Food, World Health Organization, Pharmaceutical industry, Viatris

PITTSBURGH and BANGALORE, India, Sept. 5, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced U.S. Food and Drug Administration (FDA) tentative approval for a New Drug Application for abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension for the treatment of HIV-1 infection in paediatric patients.

Key Points: 
  • According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), treatment coverage for children and adolescents lags behind adults.
  • Some 660,000 children living with HIV – about 43 percent of the estimated total 1.5 million [1.2 million–2.1 million] children living with HIV – did not receive antiretroviral (ARV) therapy in 2022.
  • Accordingly, children accounted for 13 per cent of AIDS-related deaths in 2022, even though they comprise only about 4 percent of people living with HIV.
  • The approval of this single tablet regimen – the fixed-dose combination of abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg - will reduce the pill burden for children living with HIV."

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

Retrieved on: 
Tuesday, July 11, 2023
HIV/AIDS, Bangladesh Technical Education Board, Staphylococcus aureus, Patient, PEPFAR, Infection, Walter Reed Army Institute of Research, Walter Reed Army Medical Center, Therapy, Internal medicine, CDC, Pseudomonas aeruginosa, CGMP, Allergy, Health, Pennsylvania State University, Milton Hershey School, Staphylococcus, AIDS, United States Department of the Army, Combat, President's Emergency Plan for AIDS Relief, Management, Pharmaceutical industry, Armata

MARINA DEL REY, Calif., July 11, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen‐specific bacteriophage therapeutics for antibiotic‐resistant and difficult‐to‐treat bacterial infections, today announced that it has entered into a credit and security agreement with Innoviva Strategic Opportunities LLC, a wholly‐owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"). The gross proceeds of the credit agreement at closing are $25 million before transaction‐related expenses. Armata also announced today a leadership transition whereby Dr. Deborah L. Birx will succeed Dr. Brian Varnum as the Chief Executive Officer of the Company, effective immediately. Dr. Birx will also join Armata's Board of Directors.

Key Points: 
  • Armata also announced today a leadership transition whereby Dr. Deborah L. Birx will succeed Dr. Brian Varnum as the Chief Executive Officer of the Company, effective immediately.
  • Proceeds from the $25 million new financing transaction will be used to advance the Company's pipeline of therapeutic phage candidates, including AP‐PA02 and AP‐SA02, which target infections caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively.
  • "I would also like to thank Brian for his many years of service to Armata, dating back to 2012.
  • I am excited about the recent advances and see multiple opportunities to accelerate the Company's progress and drive value creation.

South Africa - United States Collaboration Awarded Funding for Pilot Project Aimed at Democratizing the Manufacturing and Availability of Medicines in Sub-Saharan Africa

Retrieved on: 
Wednesday, March 29, 2023
Test Flight and Development Centre SAAF, University, HIV, United, COVID-19, ISP, API, Woman, Research, International development, Organization, Capacity building, MATRIX, PEPFAR, Global North and Global South, President's Emergency Plan for AIDS Relief, UCT, R, Integration, USAID, Technology transfer, Pharmaceutical industry, Fine chemical

The awarded Integrated Special Project (ISP) will support a pilot project aimed at evaluating an innovative continuous flow technology for cost-effective manufacturing of active pharmaceutical ingredients (APIs) in South Africa."

Key Points: 
  • The awarded Integrated Special Project (ISP) will support a pilot project aimed at evaluating an innovative continuous flow technology for cost-effective manufacturing of active pharmaceutical ingredients (APIs) in South Africa."
  • In fact, the vast majority of APIs for use as medicines on the African continent must be imported.
  • The team is confident that successful completion of this pilot project will lead to eventual widespread, decentralized manufacturing of medicines throughout South Africa.
  • "A successful API manufacturing industry in South Africa requires cost competitive technology; without that local manufacturing is not feasible.

Department of State Selects Palantir to Modernize Data Management for the Bureau of Medical Services

Retrieved on: 
Wednesday, March 8, 2023
BPA, Bureau, Data management, NYSE, Global health, MED, United States Department of State, United States Department of Homeland Security, State, Medicine, Bureau of Medical Services, Partnership, Health, President's Emergency Plan for AIDS Relief, Risk, PEPFAR, Safety, Axiom, Management, Palantir

DENVER, March 8, 2023 /PRNewswire/ -- Palantir Technologies Inc. (NYSE: PLTR) today announced that it has been selected by the Department of State to provide the Bureau of Medical Services (MED) with a platform for effective data management and data-driven decision-making.

Key Points: 
  • DENVER, March 8, 2023 /PRNewswire/ -- Palantir Technologies Inc. (NYSE: PLTR) today announced that it has been selected by the Department of State to provide the Bureau of Medical Services (MED) with a platform for effective data management and data-driven decision-making.
  • Palantir software will be used by MED to establish a new enterprise data management platform for the department, titled Project Axiom.
  • This new contract builds on Palantir's ongoing work with the State Department in the area of global health and medicine.
  • "We are proud to expand our partnership with the State Department and support this critical mission to safeguard our diplomatic workforce," said Mahtab Emdadi, State Department Lead at Palantir.

AHF Celebrates 20 Years of PEPFAR

Retrieved on: 
Wednesday, February 22, 2023
Public Policy, Government, AIDS, Advocacy Group Opinion, Health, Congress, HIV, President's Emergency Plan for AIDS Relief, HIV/AIDS, AHF, Patient, AIDS Healthcare Foundation, Public affairs, PEPFAR, Caregiver, Woman, Member of Congress, Pharmaceutical industry

AIDS Healthcare Foundation (AHF) celebrates PEPFAR this week as it commemorates its 20th anniversary and honors the 25 million lives it has saved while acknowledging much work remains in the global fight against HIV/AIDS.

Key Points: 
  • AIDS Healthcare Foundation (AHF) celebrates PEPFAR this week as it commemorates its 20th anniversary and honors the 25 million lives it has saved while acknowledging much work remains in the global fight against HIV/AIDS.
  • The U.S. commitment to PEPFAR, which now has programs in over 50 countries, was the most significant investment by an individual nation to combat HIV/AIDS.
  • “The world was at a tipping point in the battle against HIV, compelling AHF to advocate for the creation of PEPFAR and later its reauthorization prioritizing care and treatment.
  • It is the backbone of the global AIDS response,” added AHF Chief of Public Affairs and General Counsel Tom Myers.

Sam Hanna Joins Abt Associates as Chief Solutions Officer

Retrieved on: 
Tuesday, January 17, 2023
President's Emergency Plan for AIDS Relief, Christian Brothers University, Babson College, Digital, USAID, Senior advisor, Accounting, Entrepreneurship, Marketing, Harvard University, PEPFAR, Faculty of Medical Leadership and Management, Artificial intelligence in healthcare, American University, Knowledge, Research, Health, Dean (education), Abt, Equity, MIT, Truven Health Analytics, Intelligence, George Washington University, PricewaterhouseCoopers, Artificial intelligence, Data science, Blockchain, Information technology, Translational Health Science and Technology Institute, Management

ROCKVILLE, Md., Jan. 17, 2023 /PRNewswire-PRWeb/ -- Dr. Sam Hanna has joined Abt Associates as Chief Solutions Officer. Hanna will serve on Abt's Executive Leadership Team and will oversee the Research, Digital, Technical Assistance, and Equity teams focusing on delivering high-quality, innovative solutions to our clients' most pressing problems.

Key Points: 
  • Dr. Sam Hanna has joined Abt Associates as Chief Solutions Officer.
  • ROCKVILLE, Md., Jan. 17, 2023 /PRNewswire-PRWeb/ -- Dr. Sam Hanna has joined Abt Associates as Chief Solutions Officer.
  • Prior to USAID, he held leadership positions, including Chief Innovation, Strategy and Marketing Officer roles, at consulting firms such as PwC and Deloitte.
  • "Sam brings a wealth of knowledge and experience related to technology, health, and innovation," said Abt President and CEO Kathleen Flanagan.

Medicaid Cancer Foundation Launches Health Fund in Response to Cancer Moonshot

Retrieved on: 
Monday, January 9, 2023
Disease, Radiation, World Health Organization, Caregiver, COVID-19, HIV, LINAC, Government, PEPFAR, Particle accelerator, Patient, Cancer, Survivor, Pharmaceutical industry, African

The Medical Director of Medicaid Cancer Foundation H.E Dr. Zainab Shinkafi Bagudu has expressed her dedication to supporting cancer treatment and care in Nigeria and beyond.

Key Points: 
  • Abuja, Nigeria--(Newsfile Corp. - January 9, 2023) - Medicaid Cancer Foundation announces the launch of the Medicaid Cancer Health Fund in the wake of President Joe Biden's reignition of the cancer moonshot in February 2022.
  • The Medicaid Cancer Health Fund will broaden access to cancer care services in Northern Nigeria by linking beneficiaries to discount/free cancer services through its existing network of partners and building a comprehensive cancer treatment centre in Abuja.
  • Medicaid Cancer Foundation is committed to leveraging local and global contacts to deliver a one-stop-shop for the full complement of cancer treatment services in Nigeria.
  • The roadmap announced at the White House Cancer Moonshot Summit in December 2022 opens the door for capital and human resource investment from the United States to accelerate access to quality cancer care services in Africa.

AHF Thanks U.S. for Boosting Global Health Funding

Retrieved on: 
Friday, December 23, 2022
LGBTQ+, AIDS, Other Health, White House, Federal Government, Health, Public Policy, Other Policy Issues, Infectious Diseases, Congressional News, Views, Public Policy, Government, Consumer, Government, FY, AIDS, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Tuberculosis, HIV/AIDS, Infection, HIV, Congress, COVID-19, Pandemic, Death, Global health, AIDS Healthcare Foundation, President's Emergency Plan for AIDS Relief, PEPFAR, Fiscal year, G7, AHF, TB, Pharmaceutical industry, Malaria

AIDS Healthcare Foundation (AHF) applauded the U.S. Congress today for approving an increase in global health appropriations, including funding for HIV/AIDS and TB programs, as part of the Fiscal Year (FY) 2023 Omnibus Appropriations Bill.

Key Points: 
  • AIDS Healthcare Foundation (AHF) applauded the U.S. Congress today for approving an increase in global health appropriations, including funding for HIV/AIDS and TB programs, as part of the Fiscal Year (FY) 2023 Omnibus Appropriations Bill.
  • Congress appropriated $11.2 billion for global health in its year-end spending package, including $4.7 billion for bilateral HIV/AIDS programs and $2 billion for the Global Fund to Fight AIDS, Tuberculosis and Malaria.
  • “We thank the U.S. government for its continued strong commitment to global health, and especially for supporting the President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria.
  • “We hope that the actions by the U.S. will spur other countries, particularly our G7 partners, to follow this example and invest more in global health so that the world can be better protected against future health crises.”
    AHF has advocated for increased global public health funding since the early days of the COVID-19 pandemic.